On June 29, the China National Clinical Research Center for Neurological Diseases, the National Center for Healthcare Quality Management in Neurological Diseases, the Chinese Stroke Association, and the Neurological Artificial Intelligence Research Center held a press conference at the Beijing National Convention Center. They jointly released the BioMindTM “Tianze” cerebrovascular disease diagnosis and treatment assistance decision-making system. This is another important work after BioMindTM released the world's first neuroimaging AI-assisted diagnostic product in 2018.
The situation of prevention and control of stroke is severe
The Report on stroke Prevention and Treatment in China 2018 pointed out that the recurrence rate of the first year after the first stroke was as high as 17.1%. At the same time, during the period from 2005 to 2016, the proportion of patients under the age of 70 in the stroke population in China continued to increase, and the stroke showed a trend of gradual rejuvenation. In addition, stroke patients often lead to serious sequelae such as disability, and even without a disability, recovery treatment may be necessary for life. The per capita treatment cost of stroke patients is as high as tens of thousands of yuan, which brings a heavy burden to families and society.
Wang Yongjun, executive vice president of Beijing Tiantan Hospital and deputy director of the China National Clinical Research Center for Neurological Diseases, stressed that it is especially important to establish a unified quality control standard for the treatment and prevention of stroke.
Wang Yongjun, Executive Vice President of Beijing Tiantan Hospital, Deputy Director of the China National Clinical Research Center for Neurological Diseases
Quality control has become the key to solving the problem of stroke
In June 2018, the National Center for Healthcare Quality Management in Neurological Diseases (referred to as the National Center for Neurological Disease Quality Control) was established. It was commissioned by the Bureau of Medical Administration of the National Health Commission and settled in Beijing Tiantan Hospital. Wang Yongjun was appointed as the director of the center.
Since then, Tiantan Hospital has established the National Stroke Medical Quality Control Expert Committee, established the Regional Stroke Medical Quality Training Center and the Provincial Medical Quality Control Center, covering more than 1,800 hospitals in 29 provinces, municipalities and autonomous regions (approximately 25% of the number of public hospitals in the statistical yearbook).At the same time, Wang Yongjun team carried out a national survey of stroke medical resources. The basic data of medical resource allocation was clarified, and the important industry standard for the diagnosis and treatment quality control of ischemic stroke was established. A key indicator system for medical quality of ischemic stroke was established and popularized nationwide.
Li Zixiao, deputy director of cardiovascular neurology in neurology of Beijing Tiantan Hospital, director of quality research department of National Neurological Disease Clinical Medical Research Center
Li Zixiao, deputy director of the Department of Cardiovascular Neurology in the Department of Neurology, Beijing Tiantan Hospital, and director of the Quality Research Department of the National Center for Neurological Diseases Clinical Research, believes that through quality control, it can strengthen the multidisciplinary collaboration of medical institutions and regulate the prevention and treatment of acute phase of cerebrovascular disease. Thereby improving the prognosis of patients. It can also continuously promote the standardization and homogenization of the diagnosis and treatment of cerebrovascular diseases, provide high-quality, low-cost and accessible medical services for patients with cerebrovascular diseases, and greatly reduce the heavy disease burden of patients, families and society.
From "diagnosis" to "treatment" to "healing" the whole process assists decision-making.
On the same day, “Golden Bridge Engineering II”–a clinical controlled study based on the medical quality improvement of the “Tianze” cerebrovascular disease diagnosis and treatment assistance decision-making system was launched. At the same time, the "Chinese Cerebrovascular Disease Clinical Management Guide" was released.
"Golden Bridge Project II" means: selecting a certain sample of stroke patients, in the whole process of diagnosis and treatment, "whether or not to use 'Tianze' cerebrovascular disease diagnosis and treatment assistance decision-making system" as a control variable, set the intervention group and the control group, Compare the clinical data of cure rate, disability rate and recurrence rate.
Undoubtedly, the "Tianze" cerebrovascular disease diagnosis and treatment assistance decision-making system is expected to become an important quality control tool for further establishing and improving the clinical diagnosis and treatment of stroke.
In other words, through the close integration of “Medical + AI”, “Tian Ze” may help establish the gold standard for clinical diagnosis and treatment of stroke. So, what is its principle?
First, compared with other CDSS (Clinical Decision Support System), the “Tianze” cerebrovascular disease diagnosis and treatment assistance decision-making system includes three meanings of “diagnosis”, “therapy” and “assisted decision-making”. Namely: from the beginning of admission, the MRI/CT images of stroke patients began to be transmitted to the “Tianze” system. Using big data and AI technology, “Tianze” independently analyzed whether the stroke type was hemorrhagic or ischemic, and the location of the disease. , the pathogenesis, the etiology of the disease, combined with the patient's medical history, family history, complications and other information, give a clinical treatment assistance decision-making program. At the same time, it can provide clinicians with European and American guidelines, Chinese guides, the latest research literature and results as a reference, and continue to play a supporting role in the prognosis.
Therefore, “Tianze” is a strong combination of “AI+CDSS”, which realizes the auxiliary decision-making from the whole process of diagnosis, treatment and prognosis, and helps doctors to realize the guidance and patient data from the patient admission to discharge. Scientifically and reasonably make clinical decisions with real-time updates.
Dr. Jing Jing, Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Neuroimaging Research Center
“The meaning of ‘assisted’ is very important, and the assistance decision-making process of the whole process will be more conducive to clinical work.” Dr. Jing Jing from the Beijing Tiantan Hospital and the China National Clinical Research Center for Neurological Diseases, Neuroimaging Research Center.
“Today, when the track for assisted diagnosis is getting crowded, it is commendable that ‘Tianze’ has already achieved an upgrade of adjuvant therapy,” said Wu Zhenzhou, technical director of the Neurological Artificial Intelligence Research Center and BioMind CTO. At present, AI-assisted treatment products are being deployed in the United States, South Korea and Europe, but in China, AI-assisted treatment is still in its infancy, and the starting point for cooperation with the top hospital in Tiantan is particularly important.
Wu Zhenzhou, Technical Director of the Artificial Intelligence Research Center for Neurological Diseases, BioMind CTO
Realize the organic combination of "Tiantan experience + AI"
The National Center for Healthcare Quality Management in Neurological Diseases is the first and only national medical quality control center for neurological diseases.
The relevant person in charge of the National Health Commission has said that the reason why the center was entrusted to the Tiantan Hospital is because the Tiantan Hospital has been responsible for the quality control of the National Neurology Department for many years and has achieved remarkable results.Tiantan Hospital scored the NO.1 in all national quality control center work evaluations in 2017.The discipline construction and quality control research of neurosurgery and neurology in Tiantan Hospital are also very influential at home and abroad. In the evaluation of hospital influence of the Academy of Medical Sciences in 2017, the Department of Neurology and Neurosurgery of Tiantan Hospital won the first place.
At the same time, it is worth noting that “Tianze” is training with the help of high quality big data from Tiantan Hospital. The combination of more than 100 top experts in Tiantan's clinical experience is jointly developed with the world's top AI technical teams from Tsinghua University, Chinese Academy of Sciences, and National University of Singapore. Leading the global medical AI development trend.
The organic combination of "Tiantan Experience + AI" will surely radiate the whole country from point to plane, establish a quality control cooperation network, promote the quality of cerebrovascular disease diagnosis and treatment in different regions, promote the precision and accessibility of medical quality control, and strengthen the international influence of medical quality work.Wang Yongjun said, “‘Tianze’ will effectively promote the grading diagnosis and treatment system and high-quality medical resources to the general public, thus helping to build a healthy China and create more health and well-being for the general public.”
China National Clinical Research Center for Neurological Diseases
National Center for Healthcare Quality Management in Neurological Diseases